Drug intelligence / Profile preview

WSK-V110

Development stage: Preclinical
Lead developer: WestVac Biopharma
Modality: Recombinant Proteins and Enzymes, Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

WSK-V110 is an intranasal vaccine candidate developed for the prevention of respiratory syncytial virus (RSV) infection. It is being developed by WestVac, a biotechnology company with expertise in recombinant protein and vaccine platforms. The vaccine utilizes advanced expression systems and is designed to induce mucosal immunity against RSV through intranasal administration. Its primary indication is the prevention of RSV, a common cause of respiratory illness in infants, young children, and older adults[9].

Brand names: WSK-V110WSK-V-110WSK-V 110
Other names: Intranasal Respiratory Syncytial Virus vaccineWestVac RSV vaccine

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on WSK-V110.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WSK-V110.

Explore the full profile